Social Capital Suvretta Holdings Corp. III
Status: Deal Closed
U=S
| IPO Proceeds, $M | $250.00M |
|---|---|
| IPO Date | Jun 30, 2021 |
| CEO | Chamath Palihapitiya |
| Left Lead | Morgan Stanley |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology industry and within the organ space subsector |
| IPO Geography | Global |
| Target Company | ProKidney |
| Deal Announced | Jan 18, 2022 |
| Deal Size, $M | $1,835.00M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings | www.sec.gov |
| Approval Vote | Jul 11, 2022 |
| Amendment Vote | TBD |
| Closing Date | Jul 11, 2022 |
Formerly DNAC
PROK
| Price | $1.65 |
|---|---|
| Last closing price | $1.80 |
| H/L, today | $1.62 / $1.81 |
| H/L, 52-week | $1.45 / $14.19 |
| Volume, today | 329,783 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Social Capital Suvretta Holdings Corp. III:
- Structure and cap table
- 6 directors & officers
- 22 filings and events
- 2 underwriters
- 7 deal advisors
- 6 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Chamath Palihapitiya | 44 | Chief Executive Officer and Chairman of the Board of Directors |
| Kishan (a/k/a Kishen) Mehta | 35 | President and Director |
| James Ryans | 45 | Chief Financial Officer |
| Shoney Katz | 46 | Director of Research |
| Marc Semigran | 64 | Director |
| Uma Sinha PhD | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Morgan Stanley | BR | 19,800,000 | units |
| SoFi | 2,200,000 | ||
| 22,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.